You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,982,010


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,982,010
Title:7-dehydrocholesterol derivatives and methods using same
Abstract: The present invention provides, in certain aspects, novel 7-dehydrocholesterol (7DHC) derivatives that are useful in treating or preventing cancer, as well as in treating or preventing uncontrolled angiogenesis, in a subject. In certain embodiments of the present invention, the subject is a human. In other aspects, the present invention provides a method of preparing compounds of the invention, or a salt or solvate thereof.
Inventor(s): Singh; Rakesh K. (Barrington, RI), Moore; Richard G. (Cranston, RI)
Assignee: Women & Infants Hospital of Rhode Island (Providence, RI)
Application Number:15/302,898
Patent Claims:1. A compound of formula (I), or a salt or solvate thereof: ##STR00024## wherein in (I): R.sub.1 is CR.sub.5 or N, wherein: if R.sub.1 is CR.sub.5, then R.sub.3 is selected from the group consisting of --O(CR.sub.5).sub.nR.sub.6, --O(CR.sub.5).sub.nalkoxy, --O(CR.sub.5).sub.n+1OH, --OC(.dbd.O)(CR.sub.5).sub.nR.sub.6 and --OC(.dbd.O)(CR.sub.5).sub.nOR.sub.5 and if R.sub.1 is N, then R.sub.3 is selected from the group consisting of --O(CR.sub.5).sub.nR.sub.6, --O(CR.sub.5).sub.n+1OR.sub.5, --OC(.dbd.O)(CR.sub.5).sub.nR.sub.6 and --OC(.dbd.O)(CR.sub.5).sub.nOR.sub.5; R.sub.2 is selected from the group consisting of O, S, C(R.sub.4).sub.2, and N(R.sub.4); each occurrence of R.sub.4 is independently selected from the group consisting of H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, OR.sub.5, and N(R.sub.5).sub.2; each occurrence of R.sub.5 is independently selected from the group consisting of H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, and substituted heteroarylalkyl; R.sub.6 is selected from the group consisting of F, Cl, Br, I, mesyl, tosyl, --OSi(R.sub.5).sub.3, --C(.dbd.O)OR.sub.5, and --C(.dbd.O)R.sub.5; the dotted line is a single or double bond; and, n is an integer ranging from 1 to 5.

2. A compound of formula (I), or a salt or solvate thereof: ##STR00025## wherei in (I) R.sub.1 is N; R.sub.2 is N(R.sub.4); R.sub.3 is selected from the group consisting of --O(CR.sub.5).sub.nR.sub.6, --OC(.dbd.O)(CR.sub.5).sub.nOR.sub.5, and --OC(.dbd.O)C(R.sub.5).dbd.C(R.sub.5).sub.2; R.sub.4 is independently selected from the group consisting of H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, OR.sub.5, and N(R.sub.5).sub.2; each occurrence of R.sub.5 is independently selected from the group consisting of H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkenyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, and substituted heteroarylalkyl; R.sub.6 is selected from the group consisting of F, Cl, Br, I, mesyl, tosyl, --OSi(R.sub.5).sub.3, --C(.dbd.O)OR.sub.5, and --C(.dbd.O)R.sub.5; the dotted line is a single or double bond; and, n is an integer from 1-10.

3. The compound of claim 2, wherein the compound of formula (I) is selected from the group consisting of: ##STR00026##

4. A compound of formula (I), or a salt or solvate thereof: ##STR00027## wherein in (I): R.sub.1 is CR.sub.5; R.sub.2 is selected from the group consisting of O, S, C(R.sub.4).sub.2, and N(R.sub.4); R.sub.3 is selected from the group consisting of --N(R.sub.5).sub.2, --NO, --N(R.sub.5)N(R.sub.5).sub.2, R.sub.6, --N(R.sub.5)--OR.sub.5, --NH-C(.dbd.O)R.sub.5, alkoxy, --OSO.sub.3H, --O(CR.sub.5).sub.nalkoxy, --O(CR5).sub.n+1OH, --OC(.dbd.O)(CR.sub.5).sub.nR.sub.6, --OC(.dbd.O)(CR.sub.5).sub.nOR.sub.5, and --OC(.dbd.O)C(R.sub.5).dbd.C(R.sub.5).sub.2 or R.sub.3 is selected from the group consisting of .dbd.O and .dbd.S, and H* is omitted; each occurrence of R.sub.4 is independently selected from the group consisting of H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, OR.sub.5, and N(R.sub.5).sub.2; each occurrence of R.sub.5 is independently selected from the group consisting of H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, arylalkyl, substituted alkenyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, and substituted heteroarylalkyl; R.sub.6 is selected from the group consisting of F, Cl, Br, I, mesyl, tosyl, --OSi(R.sub.5).sub.3, --C(.dbd.O)OR.sub.5, and --C(.dbd.O)R.sub.5; the dotted line is a single or double bond; and, n is an integer from 1 to 10.

5. The compound of claim 4, wherein R.sub.5 is selected from the group consisting of H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, arylalkyl, substituted arylalkyl, heteroarylalkyl, and substituted heteroarylalkyl.

6. The compound of claim 4, wherein R.sub.3 is selected from the group consisting of R.sub.6, --O(CR.sub.5).sub.nR.sub.6, OC(.dbd.O)(CR.sub.5).sub.nR.sub.7, and OC(.dbd.O)C(R.sub.5).dbd.C(R.sub.5).sub.2; or R.sup.3 is selected from the group consisting of .dbd.O and .dbd.S, and H* is omitted.

7. The compound of any one of claims 1, 2 and 4, wherein the salt is an acid addition salt and is selected from the group consisting of sulfate, hydrogen sulfate, hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric, phosphoric, formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, trifluoromethanesulfonic, 2-hydroxyethanesulfonic, p-toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic, .beta.-hydroxybutyric, salicylic, galactaric and galacturonic acid, and any combinations thereof.

8. The compound of any one claims 1, 2 and 4 wherein the salt is a base addition salt and is selected from the group consisting of calcium, magnesium, potassium, sodium, ammonium, zinc, a basic amine salt, and any combinations thereof.

9. A pharmaceutical composition comprising the compound of any one of claims 1, 2 and 4 and a pharmaceutically acceptable carrier.

10. The composition of claim 9, further comprising at least one additional chemotherapeutic agent selected from the group consisting of alkylating agents; nitrosoureas; antimetabolites; antitumor antibiotics; plant alkyloids; taxanes; hormonal agents; anti-angiogenesis agents, and miscellaneous agents.

11. The composition of claim 9, further comprising at least one additional anti-angiogenesis agent selected from the group consisting of 2-methoxyestradiol AG3340, angiostatin, antithrombin-III, anti-VEGF antibody, VEGF antagonist, batimastat, bevacizumab, BMS-275291, CA1, canstatin, combretastatin, combretastatin-A4 phosphate, CC-5013, captopril, celecoxib, dalteparin, EMD121974, endostatin, erlotinib, gefitinib, genistein, halofuginone, ID1, ID3, IM862, omatinib mesylate, inducible protein-10, interferon-alpha, interleukin-12, lavendustin-a, LY317615, AE-941, merimastat, mapsin, medroxpregesteron acetate, Meth-1, Meth-2, Neovastat, osteopontin cleaved product, PEX, pigment epithelium growth factor, platelet growth factor 4, prolactin fragment, proliferin-related protein (PRP), PTK787/ZK222584, recombinant human platelet factor-4, restin, squalamine, SU5416, SU6668, suramin, taxol, tecogalan, thalidomide, thrombospondin, TNP-470, troponin I, vasostatin, VEGF1, VEGF-TRAP and ZD6474.

12. The composition of claim 10, wherein the compound and the agent are co-formulated in the composition.

13. A prepackaged pharmaceutical composition comprising at least one compound of any one of claims 1, 2 and 4.

14. The compound of claim 2, wherein the compound of formula (I) is ##STR00028##

15. The compound of claim 8, wherein the basic amine is selected from the group consisting of triethylamine, diisopropylethylamine, trimethylamine, N,N'-dibenzylethylene-diamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine and any combinations thereof.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.